Wednesday, February 10, 2010, 1:29am EST - Canadian Markets open in 8 hours and 1 minute.
To create a watchlist or portfolio of shares, Sign-in or Register

AVI Biopharma, Inc. (AVII)

 On Feb 9: 1.45 USD  Down 0.04 (2.68%)  
MORE ON AVII
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
AVI BioPharma, Inc. (NGM:AVII) Delayed quote dataEdit
After Hours: 1.45 0.00 (0.00%) as of 5:35pm EST on 02/09/10
Last Trade: 1.45 USD
Trade Time: Feb 9
Change: Down 0.04 (2.68%)
Prev Close: 1.49
Open: 1.49
Bid: 1.24 x 6500
Ask: 1.53 x 100
1y Target Est: 3.75
Day's Range: 1.42 - 1.51
52wk Range: 0.52 - 2.73
Volume: 733,326
Avg Vol (3m): 1,312,840
Market Cap: 160.13M
P/E (ttm): N/A
EPS (ttm): -0.36
Div & Yield: N/A (N/A%)
AVI Biopharma, Inc. (AVII)
1d  5d  3m  6m  1y  2y  5y  max 
 Add AVII to Portfolio   Download Data

HEADLINES
• UPDATE - AVI genetic disorder drug gets orphan status in EU
at Reuters (Fri, Feb 5)
• AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation for Duchenne Muscular Dystrophy
Marketwire (Fri, Feb 5)
• AVI BioPharma GLP Safety Pharmacology and Genotoxicity Evaluations of AVI-4658 for Duchenne Muscular Dystrophy Published in the International Journal of Toxicology
Marketwire (Thu, Feb 4)
• AVI BIOPHARMA INC Files SEC form 8-K, Other Events
EDGAR Online (Tue, Jan 19)
• 3 Stocks Hitting High Notes
at Motley Fool (Mon, Jan 11)
• AVI BIOPHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online (Wed, Dec 23)
• Systemic Treatment With AVI-4658 Demonstrates RNA Exon Skipping and Dystrophin Protein Expression in Duchenne Muscular Dystrophy Patients
Marketwire (Tue, Dec 22)
• AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference
Marketwire (Thu, Nov 19)
• AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative (TMTI) Industry Day
Marketwire (Wed, Nov 18)
• AVI BIOPHARMA INC Financials
EDGAR Online Financials (Fri, Nov 13)
More Headlines for AVII...
ANALYST
EPS Est (next year) (Dec-09) : -0.36
EPS Est (in 2 years) (Dec-10) : -0.23
Avg Rec (current)*: 1.5
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices